Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Helene Salaun"'
Autor:
James P. Pham, Lawrence On, Luke Ardolino, Joshua Hurwitz, Helene Salaun, Hao-Wen Sim, Anthony M. Joshua
Publikováno v:
Melanoma Research.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9ca3b49e3f461f2f06208ab83c1e01e
https://doi.org/10.1097/cmr.0000000000000900
https://doi.org/10.1097/cmr.0000000000000900
Autor:
Helene Salaun, Mathilde Poisson, Adeline Dolly, Flavie Arbion, Stéphane Servais, Jean François Dumas, Caroline Goupille, Lobna Ouldamer
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 2; Pages: 1768
Prognostic factors for epithelial ovarian cancers (EOCs) are in particular clinical factors such as pathology staging at diagnosis (FIGO stages), genetic mutation, or histological phenotypes. In the present study, FIGO stage, tumor residue after surg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b745e29842c0ac3f18022867daa6e46a
https://doi.org/10.3390/ijms24021768
https://doi.org/10.3390/ijms24021768
Autor:
Hélène Salaün, Lounes Djerroudi, Laura Haik, Anne Schnitzler, Guillaume Bataillon, Gabrielle Deniziaut, Ivan Bièche, Anne Vincent‐Salomon, Marc Debled, Paul Cottu
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER
Externí odkaz:
https://doaj.org/article/53c363172074422ebc516d2dfdc2dc90
Autor:
Hélène Salaün, Leanne de Koning, Mathilde Saint-Ghislain, Vincent Servois, Toulsie Ramtohul, Agathe Garcia, Alexandre Matet, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Manuel Rodrigues
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in m
Externí odkaz:
https://doaj.org/article/5c6e7f0d0a0c4c08a409631e649387d8